$MNOV Company News Thursday’s top gaining and

New Post Public Reply Private Reply Replies (0) Message Board

Sep 16, 2014 at 10:37 AM

$MNOV Company News

Thursday’s top gaining and declining stocks 3:24 p.m. May 24, 2012 - MarketWatch
MediciNova dives on asthma study results 12:46 p.m. May 24, 2012 - Val Brickates Kennedy
H-P climbs, NetApp tumbles in after-hours trade 6:49 p.m. May 23, 2012 - Carla Mozee
MediciNova study doesn't yield significant results 5:10 p.m. May 23, 2012 - MarketWatch.com
Drug stocks move higher in late trading 3:26 p.m. March 24, 2011 - Val Brickates Kennedy
Friday's biggest gaining and declining stocks 5:37 p.m. Aug. 21, 2009 - MarketWatch
The Gap, J.M. Smucker, Ann Taylor in view 8:33 a.m. Aug. 21, 2009 - MarketWatch
MediciNova to acquire Avigen for $1.24 a share 6:17 a.m. Aug. 21, 2009 - William L. Watts
MediciNova to buy Avigen for $1.24/share 6:03 a.m. Aug. 21, 2009 - Steve Goldstein
Avigen holders would get net cash value plus $3M 6:13 a.m. June 25, 2009 - Simon Kennedy
MediciNova, Avigen agree terms of proposed deal 6:11 a.m. June 25, 2009 - Simon Kennedy
MediciNova reaches tentative deal to buy Avigen 6:10 a.m. June 25, 2009 - Steve Goldstein
MediciNova proposes to acquire Avigen 7:10 a.m. Dec. 23, 2008 - Aude Lagorce
MediciNova makes offer for Avigen 7:07 a.m. Dec. 23, 2008 - Aude Lagorce
MediciNova reports progress in asthma-drug Phase II trial 6:25 a.m. Sept. 9, 2008 - Robert Daniel
NediciNova reports positive preliminary Phase II results 6:09 a.m. Sept. 9, 2008 - Simon Kennedy
MediciNova withdraws plan for secondary stock offering 7:32 a.m. Nov. 8, 2007 - Mike Maynard
MediciNova pulls public offering of 6M shares 7:22 a.m. Nov. 8, 2007 - Aude Lagorce
MediciNova to focus on 2 drugs, to stop asthma drug trial 6:15 a.m. June 26, 2007 - Sarah Turner
MediciNova to focus on MN-221, MN-166 6:02 a.m. June 26, 2007 - Steve Goldstein

MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog 5:00 p.m. Aug. 28, 2014 - Zacks.com
MediciNova to start ALS trial 11:52 a.m. Aug. 26, 2014 - Seeking Alpha
3 Stocks Pushing The Drugs Industry Lower 4:02 p.m. Aug. 5, 2014 - TheStreet.com
3 Drugs Stocks Pushing The Industry Higher 4:02 p.m. July 30, 2014 - TheStreet.com
10-Q: MEDICINOVA INC 5:12 p.m. May 8, 2014 - Edgar Online - (EDG = 10Q, 10K)
MediciNova: Gestation Is Slow And Uncomfortable - Birth Is Sudden And Unexpected 5:47 p.m. Feb. 25, 2014 - Seeking Alpha
MediciNova rallies on NASH study hopes 9:36 a.m. Jan. 14, 2014 - Seeking Alpha
MediciNova (MNOV) Jumps: Stock Adds 22.2% in Session - Tale of the Tape 9:51 a.m. Dec. 13, 2013 - Zacks.com
10-Q: MEDICINOVA INC 5:14 p.m. Aug. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
MediciNova Presents MN-166 Data - Analyst Blog 6:15 p.m. June 19, 2013 - Zacks.com
Stock Market Today: Big Winners & Losers for Wednesday 4:06 p.m. May 1, 2013 - 247WallSt.com
Biotech Movers: Affymax Crashes on Recall 3:40 a.m. March 4, 2013 - InvestorPlace.com
Secretive Dilution And A Possible Equity Financing From MediciNova 2:49 p.m. Feb. 27, 2013 - Seeking Alpha
4 Healthcare Stock Stories to Heal the Tuesday Blues 6:54 p.m. Feb. 26, 2013 - Wall St. Cheat Sheet
Positive Data on MediciNova's MN-221 - Analyst Blog 5:00 p.m. Aug. 24, 2012 - Zacks.com
3 Reasons This Speculative Bio-Pharma Is A Winner 5:22 p.m. Aug. 10, 2012 - Seeking Alpha
Must Know Stock Upgrades and Downgrades Today 2:51 p.m. May 24, 2012 - Wall St. Cheat Sheet
Signet Jewelers, MediciNova: Biggest Price Decliners (SIG, MNOV) 12:49 p.m. May 24, 2012 - The Wall Street Journal Interactive Edition
End Of Week Bio-Pharma Catalyst Trade And Watch List 7:55 a.m. May 4, 2012 - Seeking Alpha
Health Care Sector Wrap 4:48 p.m. May 3, 2012 - FOXBusiness

MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence 7:01 p.m. Sept. 7, 2014 - GlobeNewswire
MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) 7:01 p.m. Sept. 1, 2014 - GlobeNewswire
MediciNova to Initiate Clinical Trial of MN-166 (ibudilast) in ALS 7:01 p.m. Aug. 25, 2014 - GlobeNewswire
MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence 7:00 p.m. Aug. 18, 2014 - GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Nonalcoholic Fatty Liver Disease 7:07 p.m. Aug. 11, 2014 - GlobeNewswire
Spasticity Global Clinical Trials Review, H2, 2014 4:42 p.m. Aug. 11, 2014 - PR Newswire - PRF
MediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDA 7:31 a.m. Aug. 5, 2014 - GlobeNewswire
MediciNova to Present Data on MN-001 for the Treatment of NASH (Nonalcoholic Steatohepatitis) During the JDDW 2014 (Japan Digestive Disease Week 2014) 7:00 p.m. July 7, 2014 - GlobeNewswire
MediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary Fibrosis 7:00 p.m. June 11, 2014 - GlobeNewswire
MediciNova Announces Management Appointment 7:01 p.m. April 8, 2014 - GlobeNewswire
MediciNova Appoints Yoshio Ishizaka to its Board of Directors 7:01 p.m. April 8, 2014 - GlobeNewswire
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides 11:01 a.m. April 8, 2014 - ACCESSWIRE
MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S. 9:00 a.m. Jan. 14, 2014 - GlobeNewswire
MediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome 7:00 p.m. Nov. 11, 2013 - GlobeNewswire
MediciNova Reports Third Quarter 2013 Results 7:30 p.m. Nov. 7, 2013 - GlobeNewswire
MediciNova Appoints Yutaka Kobayashi to Its Board of Directors 5:00 p.m. Oct. 16, 2013 - GlobeNewswire
MediciNova Appoints Geoffrey O'Brien as Vice President 4:30 p.m. Oct. 16, 2013 - GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride 7:00 p.m. Oct. 6, 2013 - GlobeNewswire
National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism 7:00 p.m. Aug. 25, 2013 - GlobeNewswire
MediciNova Reports Second Quarter 2013 Results 5:30 p.m. Aug. 8, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Miranda Lambert Lights Up Red Kettle Campaign

By Logan Wright Updated Oct 25, 2026 Category News Views 112

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Tennessee's Bold Lung Cancer Trial Signals Innovation

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...